- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Gap In Mental Health Treatments: Schizophrenia
On this week’s episode, Meg Rivers, editor-in-chief, and Miranda Schmalfuhs, group social media editor, speak with Steve Paul, chairman of the board, president, and chief executive officer of Karuna Therapeutics, as well as Andrew Miller, founder and chief operating officer of Karuna Therapeutics. Miller was also one of Pharm Exec’s 2020 Emerging Pharma Leaders.
The editors speak with Paul and Miller about the following:
- Their journey into pharma
- The factors that impact their decision to pursue any individual drug product
- The mental health/disorder treatment landscape
- What treatment has been like, historically, for schizophrenia and psychosis in Alzheimer's disease
- The company’s drug, KarXT, which is being evaluated in schizophrenia and psychosis in Alzheimer's disease
- Potential marketing and commercialization challenges for KarXT
About the speakers
Dr. Steve Paul is the chairman of the board, president, and chief executive officer of Karuna Therapeutics. Paul is an expert in central nervous system drug discovery and development. He spent 17 years at Eli Lilly and Company, during which time he held several key leadership roles, including executive vice president for science and technology and president of the Lilly Research Laboratories. Prior to Lilly, Paul spent 18 years at the NIH and served as the scientific director of the National Institute of Mental Health. He is a co-founder and board member of Sage Therapeutics and a co-founder of Voyager Therapeutics where he served as president, chief executive officer.
Dr. Andrew Miller is a founder and the chief operating officer of Karuna Therapeutics as well as one of our 2020 Emerging Pharma Leaders. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. He served as a member of Karuna’s board of directors from April 2012 to March 2019. From August 2008 to July 2016, Miller held several positions at PureTech Health plc, last serving as a vice president, Venture Partner, and served as chief operating officer of Tal Medical, and the acting chief operating officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
